DMD and Duchenne muscular dystrophy: The safety and therapeutic efficacy of AON-induced skipping of native exons has been explored most thoroughly for Duchenne muscular dystrophy (caused by mutations in the DMD gene), and two AON-based treatments have recently obtained market approval by the FDA [41,42,43,44,45].